Alkermes Appoints Anne C. Whitaker to Board of Directors

Business Wire·16 Sep 2026·

·Read original

1▲0 ▼0Impact / 5

Management Biotechnology

ALKS ±

Summary · why it matters

Alkermes plc announced the appointment of Anne C. Whitaker as a new independent director to its Board of Directors. Whitaker is a seasoned biopharmaceutical executive and experienced board director, most recently serving as chief executive officer of Aerami Therapeutics, and previously holding CEO roles at Novoclem Therapeutics and Synta Pharmaceuticals, along with senior commercial and executive positions at Bausch Health Companies, Sanofi and GlaxoSmithKline. She currently serves on the boards of publicly traded Basilea Pharmaceutica and ICON plc, as well as private companies QurAlis, Bespak, Beaconcure Technologies and Trinity Partners. President and Chief Executive Officer Blair Jackson said Whitaker joins at a defining time as the company builds on strong commercial performance and advances a differentiated neuroscience pipeline, while Chairman Richard Pops cited her executive and board experience across organizations of varying sizes and stages. Alkermes, headquartered in Ireland, is a global biopharmaceutical company developing medicines in neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy.

Alkermes Plc ±